Research programme: G protein-coupled receptor agonists - Galapagos/Ferring

Drug Profile

Research programme: G protein-coupled receptor agonists - Galapagos/Ferring

Alternative Names: G protein-coupled receptor agonists - Ferring/BioFocus; GPCR agonists - BioFocus/Ferring; GPCR agonists - Ferring/BioFocus; Research programme: women's health therapeutics - Galapagos/Ferring

Latest Information Update: 22 Feb 2010

Price : $50

At a glance

  • Originator Ferring Pharmaceuticals; Galapagos NV
  • Class
  • Mechanism of Action G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Female genital diseases

Most Recent Events

  • 22 Feb 2010 Discontinued - Preclinical for Gynaecological disorders in United Kingdom (PO)
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
  • 16 Dec 2003 Preclinical trials in Gynaecological disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top